MedTrace Logo

Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)

NCT00139828 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2007-08-30

No results posted yet for this study

Summary

In this postmarketing study, the safety of Nonafact® (human coagulation factor IX) is evaluated in previous treated and untreated patients with severe, moderate or mild haemophilia B.

Conditions

  • Hemophilia B

Interventions

DRUG

human coagulation Factor IX

Sponsors & Collaborators

  • Prothya Biosolutions

    lead INDUSTRY

Principal Investigators

  • E P Mauser-Bunschoten, MD, PdD · UMC Utrecht, Van Creveldkliniek, Utrecht, The Netherlands

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-05-31
Completion
2007-02-28

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00139828 on ClinicalTrials.gov